Bie-Jia-Jian Pill: Inhibiting Tumor Glycolysis and Promoting CD8+ Cell-Mediated anti-tumor Immunity by Targeting HIF-1α-PI3K/AKT/mTOR and CCL20 in Hepatocellular Carcinoma - PubMed
5 hours ago
- #Traditional Medicine
- #Immunotherapy
- #Hepatocellular Carcinoma
- Bie-Jia-Jian Pill (BJJP) enhances anti-tumor immunity by inhibiting the Warburg effect in hepatocellular carcinoma (HCC).
- BJJP suppresses HCC cell proliferation, growth, and migration while promoting apoptosis and reducing PD-L1 expression.
- The pill enhances CD8+ T cell cytotoxicity and infiltration in tumors, synergizing with PD-L1 blockade for improved efficacy.
- BJJP targets the HIF-1α-PI3K/AKT/mTOR axis to reprogram tumor glycolysis, reducing lactate accumulation and CD8+ T cell exhaustion.
- It also inhibits NF-κB activation, down-regulates CCL20, and alleviates its inhibitory effect on CD8+ T cells.
- Combining BJJP with immunotherapy improves treatment outcomes by modulating the tumor microenvironment.